Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: High angiopoietin-2 levels are associated with greater severity and higher activity of the disease

Rheumatology

Volumn 50, Issue 4, 2011, Pages 746-755

  Michalska Jakubus, Małgorzata ^a   Kowal Bielecka, Otylia ^b   Chodorowska, Grazyna ^a   Bielecki, Marek ^b   Krasowska, Dorota ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Angiopoietins; Pathogenesis; Systemic sclerosis; Vasculopathy

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CARBON MONOXIDE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LABORATORY TEST; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTEMIC SCLEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; CAPILLARIES; CARBON MONOXIDE; CASE-CONTROL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; MIDDLE AGED; NAILS; REGRESSION ANALYSIS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 79952789457     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq392     Document Type: Article

References (45)

1. Kahaleh B. Vascular disease in scleroderma: mechanisms of vascular injury. Rheum Dis Clin North Am 2008;34: 57-71.
2. Fleming JN, Schwartz SM. The pathology of scleroderma vascular disease. Rheum Dis Clin North Am 2008;34: 41-55.
3. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132-60.
4. Koenig M, Joyal F, Fritzler MJ et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
5. Chen ZY, Silver RM, Ainsworth SK, Dobson RL, Rust P, Maricq HR. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med 1984;77: 812-22.
6. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology 2006;45(Suppl. 3):iii26-7.
7. Ashara T, Chen D, Takahashi T et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF induced postnatal neovascularization. Circ Res 1998;83: 233-40.
8. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
9. Thurston G. Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat 2002;200:575-80.
10. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001;20: 319-25.
11. Thurston G. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003;314:61-8.
12. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
13. Gamble JR, Drew J, Trezise L et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 2000;87:603-7.
14. Papapetropoulos A, García-Cardeña G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999;79:213-23.
15. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;99:11205-10.
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
17. Clements P, Lachenbruch P, Seibold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
18. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
19. Valentini G, Della Rossa A, Bombardieri S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001;60:592-8.
20. Medsger TA Jr, Steen VD. Classification, prognosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. 2nd edition. Philadelphia: Lippincott Williams & Wilkins, 1996:51-79.
21. Cutolo M, Pizzorni C, Sulli A. Nailfold video-capillaroscopy in systemic sclerosis. Z Rheumatol 2004;63:457-62.
22. Solanilla A, Villeneuve J, Auguste P et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology 2009;48: 1036-44.
23. Papapetropoulos A, Fulton D, Mahboubi K et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000;275: 9102-5.
24. Harfouche R, Hassessian HM, Guo Y et al. Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 2002;64:135-47.
25. Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A. Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 2003;139:329-36.
26. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 2001;89:477-9.
27. Fiedler U, Reiss Y, Scharpfenecker M et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006;12: 235-9.
28. Bezuidenhout L, Bracher M, Davison G, Zilla P, Davies N. Ang-2 and PDGF-BB cooperatively stimulate human peripheral blood monocyte fibrinolysis. J Leukoc Biol 2007;81:1496-503.
29. Kurosaka D, Hirai K, Nishioka M et al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 2010;37:1121-8.
30. Hashimoto T, Pittet J-F. Angiopoietin-2: modulator of vascular permeability in acute lung injury? PLoS Med 2006;3:e113.
31. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004;43:423-8.
32. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004;27:2918-24.
33. Lip PL, Chatterjee S, Caine GJ et al. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 2004;88: 1543-6.
34. Lee KW, Lip GY, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004;110:2355-60.
35. Parikh SM, Mammoto T, Schultz A et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006;3:e46.
36. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005;180:113-8.
37. Fiedler U, Scharpfenecker M, Koidl S et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004;103:4150-6.
38. Wen CY, Ito M, Chen LD et al. Expression of Tie-2 and angiopoietin-1 and -2 in early phase of ulcer healing. J Gastroenterol 2003;38:431-5.
39. Lee OH, Fueyo J, Xu J et al. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 2006;8:419-28.
40. Caramaschi P, Canestrini S, Martinelli N et al. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology 2007;46:1566-9.
41. Amarapurkar AD, Amarapurkar DN, Vibhav S, Patel ND. Angiogenesis in chronic liver disease. Ann Hepatol 2007;6: 170-3.
42. Douglas IS, Nicolls MR. Chemokine-mediated angiogenesis: an essential link in the evolution of airway fibrosis? J Clin Invest 2005;115:1133-6.
43. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139: 1049-51.
44. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001;276:26516-25.
45. Kümpers P, David S, Haubitz M et al. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis 2009; 68:1638-43.